Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery

ClinicalTrials.gov ID: NCT00636064

Public ClinicalTrials.gov record NCT00636064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind Multicenter Study of the Safety and Efficacy of Parecoxib Sodium/Valdecoxib and Placebo/Valdecoxib Compared to Placebo for Treatment of Post-Surgical Pain in Patients Who Have Coronary Bypass Graft Via Median Sternotomy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery

Study identification

NCT ID
NCT00636064
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
1,671 participants

Conditions and interventions

Conditions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2003 (Type not available)
Primary completion
Not listed
Completion
Jan 2004 (Actual)
Last update posted
Oct 10, 2008

2003 – 2004

United States locations

U.S. sites
84
U.S. states
27
U.S. cities
64
Facility City State ZIP Site status
Pfizer Investigational Site Fairhope Alabama 36532 —
Pfizer Investigational Site Mobile Alabama 36602 —
Pfizer Investigational Site Mobile Alabama 36604 —
Pfizer Investigational Site Mobile Alabama 36607 —
Pfizer Investigational Site Mobile Alabama 36608 —
Pfizer Investigational Site Tucson Arizona 85724 —
Pfizer Investigational Site Fayetteville Arkansas 72703 —
Pfizer Investigational Site Springdale Arkansas 72764 —
Pfizer Investigational Site Anaheim California 92801 —
Pfizer Investigational Site Anaheim California 92805 —
Pfizer Investigational Site Los Angeles California 90033 —
Pfizer Investigational Site Los Angeles California 90095-1778 —
Pfizer Investigational Site Orange California 92868 —
Pfizer Investigational Site Sacramento California 95819 —
Pfizer Investigational Site Sacramento California 95825 —
Pfizer Investigational Site San Francisco California 94115 —
Pfizer Investigational Site San Francisco California 94118-3110 —
Pfizer Investigational Site San Francisco California 94143-0648 —
Pfizer Investigational Site Santa Rosa California 95403 —
Pfizer Investigational Site Santa Rosa California 95404 —
Pfizer Investigational Site Stanford California 94305 —
Pfizer Investigational Site Fort Collins Colorado 80524 —
Pfizer Investigational Site Fort Collins Colorado 80528 —
Pfizer Investigational Site New Haven Connecticut 06504 —
Pfizer Investigational Site New Haven Connecticut 06520 —
Pfizer Investigational Site Washington D.C. District of Columbia 20010 —
Pfizer Investigational Site Brandon Florida 33511 —
Pfizer Investigational Site Clearwater Florida 33756 —
Pfizer Investigational Site Hudson Florida 34667 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Melbourne Florida 32901-3276 —
Pfizer Investigational Site Melbourne Florida 32901 —
Pfizer Investigational Site Pensacola Florida 32504 —
Pfizer Investigational Site Pensacola Florida 32514 —
Pfizer Investigational Site Sarasota Florida 34239 —
Pfizer Investigational Site St. Petersburg Florida 33709 —
Pfizer Investigational Site Tampa Florida 33613 —
Pfizer Investigational Site Atlanta Georgia 30322 —
Pfizer Investigational Site Augusta Georgia 30901 —
Pfizer Investigational Site Fort Wayne Indiana 46804 —
Pfizer Investigational Site Iowa City Iowa 52242 —
Pfizer Investigational Site Kansas City Kansas 66160 —
Pfizer Investigational Site Baltimore Maryland 21215 —
Pfizer Investigational Site Salisbury Maryland 21801 —
Pfizer Investigational Site Takoma Park Maryland 20912 —
Pfizer Investigational Site Towson Maryland 21204 —
Pfizer Investigational Site Boston Massachusetts 02215 —
Pfizer Investigational Site Cambridge Massachusetts 02138 —
Pfizer Investigational Site Detroit Michigan 48202 —
Pfizer Investigational Site Livonia Michigan 48150 —
Pfizer Investigational Site Muskegon Michigan 49444 —
Pfizer Investigational Site Royal Oak Michigan 48073 —
Pfizer Investigational Site New York New York 10029 —
Pfizer Investigational Site Rochester New York 14621 —
Pfizer Investigational Site Cincinnati Ohio 45219 —
Pfizer Investigational Site Cincinnati Ohio 45236 —
Pfizer Investigational Site Dayton Ohio 45408 —
Pfizer Investigational Site Dayton Ohio 45414 —
Pfizer Investigational Site Sandusky Ohio 44870 —
Pfizer Investigational Site Oklahoma City Oklahoma 73112 —
Pfizer Investigational Site Tulsa Oklahoma 74104 —
Pfizer Investigational Site Portland Oregon 97210 —
Pfizer Investigational Site Altoona Pennsylvania 16601 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15212 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15224 —
Pfizer Investigational Site Charleston South Carolina 29401 —
Pfizer Investigational Site Charleston South Carolina 29406 —
Pfizer Investigational Site Charleston South Carolina 29424 —
Pfizer Investigational Site Charleston South Carolina 29425 —
Pfizer Investigational Site Memphis Tennessee 38120 —
Pfizer Investigational Site Amarillo Texas 79106 —
Pfizer Investigational Site Fort Worth Texas 76107-2699 —
Pfizer Investigational Site Fort Worth Texas 76107 —
Pfizer Investigational Site Houston Texas 77030 —
Pfizer Investigational Site Irving Texas 75061 —
Pfizer Investigational Site Burlington Vermont 05401 —
Pfizer Investigational Site Annandale Virginia 22003 —
Pfizer Investigational Site Falls Church Virginia 22042 —
Pfizer Investigational Site Fredericksburg Virginia 22401 —
Pfizer Investigational Site Norfolk Virginia 23507 —
Pfizer Investigational Site Tacoma Washington 98405 —
Pfizer Investigational Site Elkhorn Wisconsin 53121 —
Pfizer Investigational Site Madison Wisconsin 53792 —
Pfizer Investigational Site Milwaukee Wisconsin 53215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00636064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 10, 2008 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00636064 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →